Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 10/2003

01.10.2003 | Short Communication

In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats

verfasst von: Markus Mitterhauser, Wolfgang Wadsak, Leila Wabnegger, Werner Sieghart, Helmut Viernstein, Kurt Kletter, Robert Dudczak

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

11β-Hydroxylase (CYP11B1, P45011β) plays an important role in the biosynthesis of cortisol and aldosterone and has been shown to be a good target for the in vivo imaging of adrenocortical incidentalomas in nuclear medicine. [11C]Metomidate (MTO), a potent inhibitor of this enzyme, is used for positron emission tomography (PET) imaging of adrenocortical pathology. The synthesis of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid 2-[18F]fluoroethylester (FETO), a close analogue to MTO and etomidate (ETO), has been presented recently, and the present investigation aimed to characterise the in vivo distribution of FETO. Since ETO is a well-known anaesthetic drug acting via the GABAergic system, the interaction of FETO with GABAA receptors was also evaluated. Eighteen male Sprague-Dawley rats were injected with 1.73–3.06 MBq of FETO into a tail vein after venodilatation in a 40°C water bath. Rats were sacrificed by exsanguination from the abdominal aorta under deep ether anaesthesia after 10 (n=6), 30 (n=6) or 60 min (n=6); organs were removed, weighed and counted. For binding experiments, rat cerebellar membranes were incubated for 90 min at 4°C in TC-50 buffer, 150 mM NaCl and 2 nM of [3H]flunitrazepam in the absence or presence of 10 µM diazepam or various concentrations of ETO, MTO and FETO. In vivo evaluation evinced very high uptake in the adrenal glands (7.52%±1.19% ID/g at 30 min), followed by lung (1.18%±0.19% ID/g, 10 min), liver (0.59%±0.13% ID/g, 10 min) and duodenum (0.7%±0.29% ID/g, 60 min). No defluorination nor fluoroethyl-ester cleavage was observed. When brain regions were compared with the thalamus (the reference region), highest relative uptake was seen in the cortex (2.34), followed by "rest brain" (2.13) and cerebellum (1.96). FETO and ETO were able to increase the binding of [3H]flunitrazepam with similar potencies and to a comparable extent. It is concluded that FETO shows characteristics suitable for the imaging of adrenocortical pathology with PET. Binding experiments on GABA receptors demonstrate a comparable effect of FETO and ETO. Hence, FETO possibly could also be used to elucidate the function, dynamics and kinetics of narcotic drugs with PET.
Literatur
1.
Zurück zum Zitat Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerström G, Långström B. PET imaging of adrenal cortical tumors with the 11β-hydroxylase tracer [11C]metomidate. J Nucl Med 2000; 41:275–282. Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerström G, Långström B. PET imaging of adrenal cortical tumors with the 11β-hydroxylase tracer [11C]metomidate. J Nucl Med 2000; 41:275–282.
2.
Zurück zum Zitat Bergström M, Bonasera TA, Lu L, Bergström E, Backlin C, Juhlin C, Långström B. In vitro and in vivo primate evaluation of [11C]etomidate and [11C]metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 1998; 39:982–989. Bergström M, Bonasera TA, Lu L, Bergström E, Backlin C, Juhlin C, Långström B. In vitro and in vivo primate evaluation of [11C]etomidate and [11C]metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 1998; 39:982–989.
3.
Zurück zum Zitat Mitterhauser M, Dobrozemski G, Wadsak W, Zettinig G, Viernstein H, Zolle I, Kletter K. [11C]MTO may be superior to [18F]FDG for PET imaging of metastases from adrenocortical origin [abstract]. Eur J Nucl Med 2002 [Suppl 1]; 29:S372. Mitterhauser M, Dobrozemski G, Wadsak W, Zettinig G, Viernstein H, Zolle I, Kletter K. [11C]MTO may be superior to [18F]FDG for PET imaging of metastases from adrenocortical origin [abstract]. Eur J Nucl Med 2002 [Suppl 1]; 29:S372.
4.
Zurück zum Zitat Zettinig G, Mitterhauser M, Wadsak W, Dobrozemsky G, Pirich C, Dudczak R, Niederle B, Kletter K. Imaging of adrenal masses with C11-metomidate PET: preliminary results from Vienna [abstract]. Eur J Nucl Med 2002 [Suppl 1]; 29:S80. Zettinig G, Mitterhauser M, Wadsak W, Dobrozemsky G, Pirich C, Dudczak R, Niederle B, Kletter K. Imaging of adrenal masses with C11-metomidate PET: preliminary results from Vienna [abstract]. Eur J Nucl Med 2002 [Suppl 1]; 29:S80.
5.
Zurück zum Zitat Wadsak W, Mitterhauser M. Synthesis of [18F]FETO, a novel potential 11-β hydroxylase inhibitor. J Lab Compd Radpharm 2003; 46:379–388.CrossRef Wadsak W, Mitterhauser M. Synthesis of [18F]FETO, a novel potential 11-β hydroxylase inhibitor. J Lab Compd Radpharm 2003; 46:379–388.CrossRef
6.
Zurück zum Zitat Hammerschmidt F, Berger ML, Peric-Simov B, Schirbel A, Zolle I. Synthesis of etomidate analogues by a new stereoselective approach and structure-activity studies. SNM Annual Congress 2003; meeting abstract 167. Hammerschmidt F, Berger ML, Peric-Simov B, Schirbel A, Zolle I. Synthesis of etomidate analogues by a new stereoselective approach and structure-activity studies. SNM Annual Congress 2003; meeting abstract 167.
7.
Zurück zum Zitat Slany A, Zezula J, Fuchs K, Sieghart W. Allosteric modulation of [3H]flunitrazepam binding to recombinant GABAA receptors. Eur J Pharmacol 1995; 291:99–105.CrossRefPubMed Slany A, Zezula J, Fuchs K, Sieghart W. Allosteric modulation of [3H]flunitrazepam binding to recombinant GABAA receptors. Eur J Pharmacol 1995; 291:99–105.CrossRefPubMed
8.
Zurück zum Zitat Perkins LM, Payne AH. Quantification of P450scc, P450(17) alpha, and iron sulfur protein reductase in Leydig cells and adrenals of inbred strains of mice. Endocrinology 1988; 123:2675–2682.PubMed Perkins LM, Payne AH. Quantification of P450scc, P450(17) alpha, and iron sulfur protein reductase in Leydig cells and adrenals of inbred strains of mice. Endocrinology 1988; 123:2675–2682.PubMed
9.
Zurück zum Zitat Magata Y, Kitano H, Shiozaki T, Iida Y, Nishizawa S, Saji H, Konishi J. Effect of chronic (-)-nicotine treatment on rat cerebral benzodiazepine receptors. Nucl Med Biol 2000; 27:57–60.CrossRefPubMed Magata Y, Kitano H, Shiozaki T, Iida Y, Nishizawa S, Saji H, Konishi J. Effect of chronic (-)-nicotine treatment on rat cerebral benzodiazepine receptors. Nucl Med Biol 2000; 27:57–60.CrossRefPubMed
10.
Zurück zum Zitat Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 1995; 47:181–234.PubMed Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 1995; 47:181–234.PubMed
Metadaten
Titel
In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats
verfasst von
Markus Mitterhauser
Wolfgang Wadsak
Leila Wabnegger
Werner Sieghart
Helmut Viernstein
Kurt Kletter
Robert Dudczak
Publikationsdatum
01.10.2003
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2003
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1252-8

Weitere Artikel der Ausgabe 10/2003

European Journal of Nuclear Medicine and Molecular Imaging 10/2003 Zur Ausgabe